Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on June 10, 2002

Circulation. 2002
Published online before print June 10, 2002, doi: 10.1161/01.CIR.0000019737.87850.5A
A more recent version of this article appeared on July 2, 2002
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
106/1/63    most recent
01.CIR.0000019737.87850.5Av1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Björklund, K.
Right arrow Articles by Lithell, H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Björklund, K.
Right arrow Articles by Lithell, H.
Related Collections
Right arrow Lipids
Right arrow Obesity
Right arrow Other hypertension
Right arrow Hypertrophy
Right arrow Glucose intolerance
Right arrow Other etiology

Submitted on March 7, 2002
Revised on April 11, 2002
Accepted on April 15, 2002

Different Metabolic Predictors of White-Coat and Sustained Hypertension Over a 20-Year Follow-Up Period. A Population-Based Study of Elderly Men

Kristina Björklund MD*, Lars Lind MD, PhD, Bengt Vessby MD, PhD, Bertil Andrén MD, PhD, and Hans Lithell MD, PhD

From the Departments of Public Health and Caring Sciences/Section of Geriatrics (K.B., B.V., H.L.) and Medical Sciences (L.L., B.A.), University of Uppsala, Sweden.

* To whom correspondence should be addressed. E-mail: Kristina.Bjorklund{at}pubcare.uu.se.

Background—The clinical significance of white-coat hypertension is still unclear. Moreover, no study has examined metabolic predictors of white-coat versus sustained hypertension.

Methods and Results—We investigated men (n=602) in a longitudinal population-based cohort who at age 70 years were identified as normotensive, white-coat hypertensive (office blood pressure [BP] >=140/90 and daytime ambulatory BP <135/85 mm Hg), and sustained hypertensive (office BP >=140/90 and daytime ambulatory BP >=135/85 mm Hg). At baseline, when the subjects were aged 50 years, blood glucose, insulin, lipids, and fatty acid composition of the serum cholesterol esters were analyzed. The investigations at age 70 years included determination of insulin sensitivity and target organ damage. At age 50 years, individuals who 20 years later were identified as white-coat hypertensive or sustained hypertensive showed significantly elevated BP, heart rate, and impaired glucose tolerance compared with normotensive subjects but white coat hypertensive subjects were leaner and had a more favorable serum cholesterol ester fatty acid profile than did sustained hypertensive subjects. At age 70 years, both white-coat and sustained hypertensive subjects showed an impaired insulin sensitivity, elevated blood glucose, and increased serum insulin and heart rate compared with normotensive subjects, but left ventricular mass and urinary albumin excretion were increased only in sustained hypertensive subjects.

Conclusions—These findings indicate that although metabolic abnormalities and elevated heart rate were consistent over time in both hypertensive groups, a lower body mass index and more favorable dietary fat composition predicted the development of white-coat as opposed to sustained hypertension over 20 years.


Key words: hypertension • fatty acids • insulin




This article has been cited by other articles:


Home page
HypertensionHome page
L. R. Krakoff
Cost-Effectiveness of Ambulatory Blood Pressure: A Reanalysis
Hypertension, January 1, 2006; 47(1): 29 - 34.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. Ota, Y. Sawa, S. Iwai, T. Kitajima, Y. Ueda, C. Coppin, H. Matsuda, and Y. Okita
Fibronectin-Hepatocyte Growth Factor Enhances Reendothelialization in Tissue-Engineered Heart Valve
Ann. Thorac. Surg., November 1, 2005; 80(5): 1794 - 1801.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Ohkubo, M. Kikuya, H. Metoki, K. Asayama, T. Obara, J. Hashimoto, K. Totsune, H. Hoshi, H. Satoh, and Y. Imai
Prognosis of "Masked" Hypertension and "White-Coat" Hypertension Detected by 24-h Ambulatory Blood Pressure Monitoring: 10-Year Follow-Up From the Ohasama Study
J. Am. Coll. Cardiol., August 2, 2005; 46(3): 508 - 515.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
T. Ugajin, A. Hozawa, T. Ohkubo, K. Asayama, M. Kikuya, T. Obara, H. Metoki, H. Hoshi, J. Hashimoto, K. Totsune, et al.
White-Coat Hypertension as a Risk Factor for the Development of Home Hypertension: The Ohasama Study
Arch Intern Med, July 11, 2005; 165(13): 1541 - 1546.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
H. O. Ventura and M. R. Mehra
White Coat Hypertension and Sleep Apnea: Is There a Link?
Chest, March 1, 2004; 125(3): 805 - 807.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. H. Rahimtoola
The year in valvular heart disease
J. Am. Coll. Cardiol., February 4, 2004; 43(3): 491 - 504.
[Full Text] [PDF]